These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 24166229)

  • 1. Evaluation of disproportionality safety signaling applied to healthcare databases.
    DuMouchel W; Ryan PB; Schuemie MJ; Madigan D
    Drug Saf; 2013 Oct; 36 Suppl 1():S123-32. PubMed ID: 24166229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empirical performance of the case-control method: lessons for developing a risk identification and analysis system.
    Madigan D; Schuemie MJ; Ryan PB
    Drug Saf; 2013 Oct; 36 Suppl 1():S73-82. PubMed ID: 24166225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of the empirical performance of methods for a risk identification system.
    Ryan PB; Stang PE; Overhage JM; Suchard MA; Hartzema AG; DuMouchel W; Reich CG; Schuemie MJ; Madigan D
    Drug Saf; 2013 Oct; 36 Suppl 1():S143-58. PubMed ID: 24166231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defining a reference set to support methodological research in drug safety.
    Ryan PB; Schuemie MJ; Welebob E; Duke J; Valentine S; Hartzema AG
    Drug Saf; 2013 Oct; 36 Suppl 1():S33-47. PubMed ID: 24166222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative outcome definitions and their effect on the performance of methods for observational outcome studies.
    Reich CG; Ryan PB; Schuemie MJ
    Drug Saf; 2013 Oct; 36 Suppl 1():S181-93. PubMed ID: 24166234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of drug and outcome prevalence on the feasibility and performance of analytical methods for a risk identification and analysis system.
    Reich CG; Ryan PB; Suchard MA
    Drug Saf; 2013 Oct; 36 Suppl 1():S195-204. PubMed ID: 24166235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empirical performance of the calibrated self-controlled cohort analysis within temporal pattern discovery: lessons for developing a risk identification and analysis system.
    Norén GN; Bergvall T; Ryan PB; Juhlin K; Schuemie MJ; Madigan D
    Drug Saf; 2013 Oct; 36 Suppl 1():S107-21. PubMed ID: 24166228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empirical performance of LGPS and LEOPARD: lessons for developing a risk identification and analysis system.
    Schuemie MJ; Madigan D; Ryan PB
    Drug Saf; 2013 Oct; 36 Suppl 1():S133-42. PubMed ID: 24166230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Replication of the OMOP experiment in Europe: evaluating methods for risk identification in electronic health record databases.
    Schuemie MJ; Gini R; Coloma PM; Straatman H; Herings RM; Pedersen L; Innocenti F; Mazzaglia G; Picelli G; van der Lei J; Sturkenboom MC
    Drug Saf; 2013 Oct; 36 Suppl 1():S159-69. PubMed ID: 24166232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empirical assessment of case-based methods for drug safety alert identification in the French National Healthcare System database (SNDS): Methodology of the ALCAPONE project.
    Thurin NH; Lassalle R; Schuemie M; Pénichon M; Gagne JJ; Rassen JA; Benichou J; Weill A; Blin P; Moore N; Droz-Perroteau C
    Pharmacoepidemiol Drug Saf; 2020 Sep; 29(9):993-1000. PubMed ID: 32133717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empirical performance of a self-controlled cohort method: lessons for developing a risk identification and analysis system.
    Ryan PB; Schuemie MJ; Madigan D
    Drug Saf; 2013 Oct; 36 Suppl 1():S95-106. PubMed ID: 24166227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Empirical performance of a new user cohort method: lessons for developing a risk identification and analysis system.
    Ryan PB; Schuemie MJ; Gruber S; Zorych I; Madigan D
    Drug Saf; 2013 Oct; 36 Suppl 1():S59-72. PubMed ID: 24166224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disproportionality Analysis for Pharmacovigilance Signal Detection in Small Databases or Subsets: Recommendations for Limiting False-Positive Associations.
    Caster O; Aoki Y; Gattepaille LM; Grundmark B
    Drug Saf; 2020 May; 43(5):479-487. PubMed ID: 32008183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empirical performance of the self-controlled case series design: lessons for developing a risk identification and analysis system.
    Suchard MA; Zorych I; Simpson SE; Schuemie MJ; Ryan PB; Madigan D
    Drug Saf; 2013 Oct; 36 Suppl 1():S83-93. PubMed ID: 24166226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Desideratum for evidence based epidemiology.
    Overhage JM; Ryan PB; Schuemie MJ; Stang PE
    Drug Saf; 2013 Oct; 36 Suppl 1():S5-14. PubMed ID: 24166219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating performance of risk identification methods through a large-scale simulation of observational data.
    Ryan PB; Schuemie MJ
    Drug Saf; 2013 Oct; 36 Suppl 1():S171-80. PubMed ID: 24166233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
    Welch HK; Kellum JA; Kane-Gill SL
    Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database.
    Brinker AD; Lyndly J; Tonning J; Moeny D; Levine JG; Avigan MI
    Drug Saf; 2013 Dec; 36(12):1169-78. PubMed ID: 24178291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using Rich Data on Comorbidities in Case-Control Study Design with Electronic Health Record Data Improves Control of Confounding in the Detection of Adverse Drug Reactions.
    Backenroth D; Chase H; Friedman C; Wei Y
    PLoS One; 2016; 11(10):e0164304. PubMed ID: 27716785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How well do various health outcome definitions identify appropriate cases in observational studies?
    Hansen RA; Gray MD; Fox BI; Hollingsworth JC; Gao J; Zeng P
    Drug Saf; 2013 Oct; 36 Suppl 1():S27-32. PubMed ID: 24166221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.